Oryzon Genomics is a clinical-stage biopharmaceutical company focused on developing epigenetic therapies for cancer and central nervous system diseases. The company's pipeline includes novel inhibitors of histone deacetylases (HDACs) and lysine demethylases (KDMs) that regulate gene expression. Oryzon's lead compounds are being tested in clinical trials for various oncology indications and neurodegenerative diseases including Alzheimer's disease. The company is publicly traded on the Spanish stock exchange and has partnerships with major pharmaceutical companies for drug development and commercialization.
Oryzon Genomics has received investment from 1 venture capital firm.
Spanish biopharmaceutical company developing epigenetic therapies for cancer and CNS diseases using histone deacetylase and lysine demethylase inhibitors.
Oryzon Genomics has received investment from Asabys Partners. These venture capital firms and investors provide both capital and strategic support.
Oryzon Genomics has raised $50M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Oryzon Genomics was founded in 2000 and is headquartered in Barcelona, Spain.
Oryzon Genomics operates in the Biotech sector. Spanish biopharmaceutical company developing epigenetic therapies for cancer and CNS diseases using histone deacetylase and lysine demethylase inhibitors.
